Association between C-reactive protein and risk of cancer: A meta-analysis of prospective cohort studies

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 1, 2013, Pages 243-248

  Guo, Yong Zhong ^a   Pan, Lei ^b   Du, Chang Jun ^a   Ren, Dun Qiang ^c   Xie, Xiao Mei ^a  

^a XUZHOU CENTRAL HOSPITAL   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c QINGDAO UNIVERSITY   (China)

Author keywords

C reactive protein; Cancer; Cohort studies; Meta analysis

Indexed keywords

EID: 84877139974     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.1.243     Document Type: Article

References (42)

1. Aleksandrova K, Jenab M, Boeing H, et al (2010). Circulating C-reactive protein concentrations and risks of colon and rectal cancer: a nested case-control study within the European Prospective Investigation into Cancer and Nutrition. Am J Epidemiol, 172, 407-18.
2. Allin KH, Bojesen SE, Nordestgaard BG (2009). Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol, 27, 2217-24.
3. Allin KH, Nordestgaard BG, Zacho J, Tybjaerg-Hansen A, Bojesen SE (2010). C-reactive protein and the risk of cancer: a mendelian randomization study. J Natl Cancer Inst, 102, 202-6.
4. Allin KH, Bojesen SE, Johansen JS, Nordestgaard BG (2012). Cancer risk by combined levels of YKL-40 and C-reactive protein in the general population. Br J Cancer, 106, 199-205.
5. Austin PC, Anderson GM, Cigsar C, Gruneir A (2012). Comparing the cohort design and the nested case-control design in the presence of both time-invariant and time-dependent treatment and competing risks: bias and precision. Pharmacoepidemiol Drug Saf, 21, 714-24.
6. Babu SN, Chetal G, Kumar S (2012). Macrophage migration inhibitory factor: a potential marker for cancer diagnosis and therapy. Asian Pac J Cancer Prev, 13, 1737-44.
7. Balkwill F, Mantovani A (2001). Inflammation and cancer: back to Virchow? Lancet, 357, 539-45.
8. Ben-Baruch A (2003). Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res, 5, 31-6.
9. Bianchini F, Kaaks R, Vainio H (2002). Overweight, obesity, and cancer risk. Lancet Oncol, 3, 565-74.
10. Bochud M, Rousson V (2010). Usefulness of Mendelian randomization in observational epidemiology. Int J Environ Res Public Health, 7, 711-28.
11. Chaturvedi AK, Caporaso NE, Katki HA, et al (2010). C-reactive protein and risk of lung cancer. J Clin Oncol, 28, 2719-26.
12. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009). Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis, 30, 1073-81.
13. Dos SSI, De Stavola BL, Pizzi C, Meade TW (2010). Circulating levels of coagulation and inflammation markers and cancer risks: individual participant analysis of data from three long-term cohorts. Int J Epidemiol, 39, 699-709.
14. Duval S, Tweedie R (2000). Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics, 56, 455-63.
15. Greenland S, Longnecker MP (1992). Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol, 135, 1301-9.
16. Gunter MJ, Stolzenberg-Solomon R, Cross AJ, et al (2006). A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res, 66, 2483-7.
17. Gur T, Demir H, Kotan MC (2011). Tumor markers and biochemical parameters in colon cancer patients before and after chemotherapy. Asian Pac J Cancer Prev, 12, 3147-50.
18. Haverkamp J, Charbonneau B, Ratliff TL (2008). Prostate inflammation and its potential impact on prostate cancer: a current review. J Cell Biochem, 103, 1344-53.
19. Heikkila K, Harris R, Lowe G, et al (2009). Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control, 20, 15-26.
20. Heikkila K, Silander K, Salomaa V, et al (2011). C-reactive protein-associated genetic variants and cancer risk: findings from FINRISK 1992, FINRISK 1997 and Health 2000 studies. Eur J Cancer, 47, 404-12.
21. Helzlsouer KJ, Erlinger TP, Platz EA (2006). C-reactive protein levels and subsequent cancer outcomes: results from a prospective cohort study. Eur J Cancer, 42, 704-7.
22. Higgins JPT, Sally Green P (2011). Cochrane handbook for systematic reviews of interventions. New York: John Wiley \& Sons.
23. Il'Yasova D, Colbert LH, Harris TB, et al (2005). Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev, 14, 2413-8.
24. Lee S, Choe JW, Kim HK, Sung J (2011). High-sensitivity C-reactive protein and cancer. J Epidemiol, 21, 161-8.
25. Lubin JH, Alavanja MC, Caporaso N, et al (2007). Cigarette smoking and cancer risk: modeling total exposure and intensity. Am J Epidemiol, 166, 479-89.
26. Mantovani A, Allavena P, Sica A, Balkwill F (2008). Cancer-related inflammation. Nature, 454, 436-44.
27. Moore MM, Chua W, Charles KA, Clarke SJ (2010). Inflammation and cancer: causes and consequences. Clin Pharmacol Ther, 87, 504-8.
28. Orsini N, Bellocco R, Greenland S (2006). Generalized least squares for trend estimation of summarized dose-response data. Stata J, 6, 40-57.
29. Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S (2006). Plasma C-reactive protein and risk of colorectal cancer in a nested case-control study: Japan Public Health Center-based prospective study. Cancer Epidemiol Biomarkers Prev, 15, 690-5.
30. Pearson TA, Mensah GA, Alexander RW, et al (2003). Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 107, 499-511.
31. Pierce BL, Biggs ML, DeCambre M, et al (2009). C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older. Cancer Causes Control, 20, 1193-203.
32. Pine SR, Mechanic LE, Enewold L, et al (2011). Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst, 103, 1112-22.
33. Platz EA, De Marzo AM, Erlinger TP, et al (2004). No association between pre-diagnostic plasma C-reactive protein concentration and subsequent prostate cancer. Prostate, 59, 393-400.
34. Prizment AE, Anderson KE, Visvanathan K, Folsom AR (2011). Association of inflammatory markers with colorectal cancer incidence in the atherosclerosis risk in communities study. Cancer Epidemiol Biomarkers Prev, 20, 297-307.
35. Proctor MJ, Talwar D, Balmar SM, et al (2010). The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study. Br J Cancer, 103, 870-6.
36. Sgambato A, Cittadini A (2010). Inflammation and cancer: a multifaceted link. Eur Rev Med Pharmacol Sci, 14, 263-8.
37. Siemes C, Visser LE, Coebergh JW, et al (2006). C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol, 24, 5216-22.
38. Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P (2006). Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev, 15, 381-4.
39. Tsilidis KK, Branchini C, Guallar E, et al (2008). C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer, 123, 1133-40.
40. Van Hemelrijck M, Holmberg L, Garmo H, et al (2011). Association between levels of C-reactive protein and leukocytes and cancer: three repeated measurements in the Swedish AMORIS study. Cancer Epidemiol Biomarkers Prev, 20, 428-37.
41. Zhang SM, Buring JE, Lee IM, Cook NR, Ridker PM (2005). C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Intern Med, 142, 425-32.
42. Zhang SM, Lin J, Cook NR, et al (2007). C-reactive protein and risk of breast cancer. J Natl Cancer Inst, 99, 890-4.